Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis

Takashi Taniguchi, Yoshihide Asano, Takemichi Fukasawa, Ayumi Yoshizaki, Shinichi Sato

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

Reflecting the critical role of interleukin (IL)-6 in systemic sclerosis (SSc), tocilizumab, an anti-IL-6 receptor antibody, is currently under a global phase III trial against skin sclerosis of this disease. We here demonstrate that the IL-6/signal transducer and activator of transcription 3 axis is broadly activated in various cell types in the lesional skin of SSc patients irrespective of disease subtypes, especially in endothelial cells. Importantly, 12 monthly infusions of tocilizumab improved nailfold capillary changes as well as skin sclerosis in a patient with diffuse cutaneous SSc. The present findings suggest a potential disease-modifying effect of tocilizumab on SSc vasculopathy.

Original languageEnglish
Pages (from-to)967-971
Number of pages5
JournalJournal of Dermatology
Volume44
Issue number8
DOIs
Publication statusPublished - 2017 Aug

Keywords

  • interleukin-6
  • signal transducer and activator of transcription 3
  • systemic sclerosis
  • tocilizumab
  • vasculopathy

Fingerprint

Dive into the research topics of 'Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis'. Together they form a unique fingerprint.

Cite this